Immunotargeting of streptavidin to the pulmonary endothelium

V. R. Muzykantov, Elena Nikolaevna Atochina, V. Gavriljuk, S. M. Danilov, A. B. Fisher

Research output: Contribution to journalArticle

15 Citations (Scopus)

Abstract

We have observed previously that monoclonal antibody to angiotensin- converting enzyme (Mab 9B9) accumulates selectively in the lung after intravenous injection. The objective of the present work is the development of a universal system for targeting of drug or radiolabel to the lung, using biotinylated Mab 9B9 and streptavidin. Methods: Mab 9B9 was biotinylated with biotin succinimide ester (b-Mab 9B9), while streptavidin (SA) was radiolabeled with 125I. Interaction between b-Mab 9B9 and SA has been estimated in solid-phase radioassay. Radiolabeled SA was conjugated with b- Mab 9B9 or with b-IgG and injected intravenously in rats or perfused in isolated rat lungs. Results: Radiolabeled b-Mab 9B9 biotinylated at biotin- to-antibody molar ratio 10 (b-Mab 9B9) retains its ability to accumulate in rat lungs after intravenous injection. Radiolabeled SA conjugated with b-Mab 9B9 accumulates in the lung tissue in perfused isolated rat lungs. About 20% of injected SA accumulates in the rat lung 1 hr after intravenous injection (localization ratio is 20, immunospecificity of the conjugate pulmonary uptake is 70). As compared with conjugate injection, stepwise intravenous injection of b-Mab 9B9 and radiolabeled SA leads to a marked reduction of SA pulmonary uptake. Maximal pulmonary uptake of Mab 9B9 has been observed 2-3 hr after intravenous injection, while 24 hr later, radioactivity in the lung was markedly reduced. In contrast to radiolabeled Mab 9B9 alone, radiolabeled SA conjugated with b-Mab 9B9 was retained in the lung for at least 48 hr. In concert with effective blood clearance of the conjugate, its prolonged lung retention leads to a marked increase in its lung-to-blood ratio: 80 for SA- b-Mab 9B9 versus 15-20 for Mab 9B9. Conclusion: Conjugation of Mab 9B9 with streptavidin enhances selective pulmonary uptake of the preparation, providing a background for intrapulmonary immunotargeting of various biotinylated agents.

Original languageEnglish
Pages (from-to)1358-1365
Number of pages8
JournalJournal of Nuclear Medicine
Volume35
Issue number8
Publication statusPublished - 1994
Externally publishedYes

Fingerprint

Streptavidin
Endothelium
Lung
Intravenous Injections
Biotin
Peptidyl-Dipeptidase A
Drug Delivery Systems
Radioactivity

Keywords

  • angiotensin-converting enzyme
  • biotinylated antibody
  • endothelium
  • lung
  • streptavidin

ASJC Scopus subject areas

  • Radiological and Ultrasound Technology

Cite this

Muzykantov, V. R., Atochina, E. N., Gavriljuk, V., Danilov, S. M., & Fisher, A. B. (1994). Immunotargeting of streptavidin to the pulmonary endothelium. Journal of Nuclear Medicine, 35(8), 1358-1365.

Immunotargeting of streptavidin to the pulmonary endothelium. / Muzykantov, V. R.; Atochina, Elena Nikolaevna; Gavriljuk, V.; Danilov, S. M.; Fisher, A. B.

In: Journal of Nuclear Medicine, Vol. 35, No. 8, 1994, p. 1358-1365.

Research output: Contribution to journalArticle

Muzykantov, VR, Atochina, EN, Gavriljuk, V, Danilov, SM & Fisher, AB 1994, 'Immunotargeting of streptavidin to the pulmonary endothelium', Journal of Nuclear Medicine, vol. 35, no. 8, pp. 1358-1365.
Muzykantov VR, Atochina EN, Gavriljuk V, Danilov SM, Fisher AB. Immunotargeting of streptavidin to the pulmonary endothelium. Journal of Nuclear Medicine. 1994;35(8):1358-1365.
Muzykantov, V. R. ; Atochina, Elena Nikolaevna ; Gavriljuk, V. ; Danilov, S. M. ; Fisher, A. B. / Immunotargeting of streptavidin to the pulmonary endothelium. In: Journal of Nuclear Medicine. 1994 ; Vol. 35, No. 8. pp. 1358-1365.
@article{669f31eddd5a4170ac9edc664fbf2430,
title = "Immunotargeting of streptavidin to the pulmonary endothelium",
abstract = "We have observed previously that monoclonal antibody to angiotensin- converting enzyme (Mab 9B9) accumulates selectively in the lung after intravenous injection. The objective of the present work is the development of a universal system for targeting of drug or radiolabel to the lung, using biotinylated Mab 9B9 and streptavidin. Methods: Mab 9B9 was biotinylated with biotin succinimide ester (b-Mab 9B9), while streptavidin (SA) was radiolabeled with 125I. Interaction between b-Mab 9B9 and SA has been estimated in solid-phase radioassay. Radiolabeled SA was conjugated with b- Mab 9B9 or with b-IgG and injected intravenously in rats or perfused in isolated rat lungs. Results: Radiolabeled b-Mab 9B9 biotinylated at biotin- to-antibody molar ratio 10 (b-Mab 9B9) retains its ability to accumulate in rat lungs after intravenous injection. Radiolabeled SA conjugated with b-Mab 9B9 accumulates in the lung tissue in perfused isolated rat lungs. About 20{\%} of injected SA accumulates in the rat lung 1 hr after intravenous injection (localization ratio is 20, immunospecificity of the conjugate pulmonary uptake is 70). As compared with conjugate injection, stepwise intravenous injection of b-Mab 9B9 and radiolabeled SA leads to a marked reduction of SA pulmonary uptake. Maximal pulmonary uptake of Mab 9B9 has been observed 2-3 hr after intravenous injection, while 24 hr later, radioactivity in the lung was markedly reduced. In contrast to radiolabeled Mab 9B9 alone, radiolabeled SA conjugated with b-Mab 9B9 was retained in the lung for at least 48 hr. In concert with effective blood clearance of the conjugate, its prolonged lung retention leads to a marked increase in its lung-to-blood ratio: 80 for SA- b-Mab 9B9 versus 15-20 for Mab 9B9. Conclusion: Conjugation of Mab 9B9 with streptavidin enhances selective pulmonary uptake of the preparation, providing a background for intrapulmonary immunotargeting of various biotinylated agents.",
keywords = "angiotensin-converting enzyme, biotinylated antibody, endothelium, lung, streptavidin",
author = "Muzykantov, {V. R.} and Atochina, {Elena Nikolaevna} and V. Gavriljuk and Danilov, {S. M.} and Fisher, {A. B.}",
year = "1994",
language = "English",
volume = "35",
pages = "1358--1365",
journal = "Journal of Nuclear Medicine",
issn = "0161-5505",
publisher = "Society of Nuclear Medicine Inc.",
number = "8",

}

TY - JOUR

T1 - Immunotargeting of streptavidin to the pulmonary endothelium

AU - Muzykantov, V. R.

AU - Atochina, Elena Nikolaevna

AU - Gavriljuk, V.

AU - Danilov, S. M.

AU - Fisher, A. B.

PY - 1994

Y1 - 1994

N2 - We have observed previously that monoclonal antibody to angiotensin- converting enzyme (Mab 9B9) accumulates selectively in the lung after intravenous injection. The objective of the present work is the development of a universal system for targeting of drug or radiolabel to the lung, using biotinylated Mab 9B9 and streptavidin. Methods: Mab 9B9 was biotinylated with biotin succinimide ester (b-Mab 9B9), while streptavidin (SA) was radiolabeled with 125I. Interaction between b-Mab 9B9 and SA has been estimated in solid-phase radioassay. Radiolabeled SA was conjugated with b- Mab 9B9 or with b-IgG and injected intravenously in rats or perfused in isolated rat lungs. Results: Radiolabeled b-Mab 9B9 biotinylated at biotin- to-antibody molar ratio 10 (b-Mab 9B9) retains its ability to accumulate in rat lungs after intravenous injection. Radiolabeled SA conjugated with b-Mab 9B9 accumulates in the lung tissue in perfused isolated rat lungs. About 20% of injected SA accumulates in the rat lung 1 hr after intravenous injection (localization ratio is 20, immunospecificity of the conjugate pulmonary uptake is 70). As compared with conjugate injection, stepwise intravenous injection of b-Mab 9B9 and radiolabeled SA leads to a marked reduction of SA pulmonary uptake. Maximal pulmonary uptake of Mab 9B9 has been observed 2-3 hr after intravenous injection, while 24 hr later, radioactivity in the lung was markedly reduced. In contrast to radiolabeled Mab 9B9 alone, radiolabeled SA conjugated with b-Mab 9B9 was retained in the lung for at least 48 hr. In concert with effective blood clearance of the conjugate, its prolonged lung retention leads to a marked increase in its lung-to-blood ratio: 80 for SA- b-Mab 9B9 versus 15-20 for Mab 9B9. Conclusion: Conjugation of Mab 9B9 with streptavidin enhances selective pulmonary uptake of the preparation, providing a background for intrapulmonary immunotargeting of various biotinylated agents.

AB - We have observed previously that monoclonal antibody to angiotensin- converting enzyme (Mab 9B9) accumulates selectively in the lung after intravenous injection. The objective of the present work is the development of a universal system for targeting of drug or radiolabel to the lung, using biotinylated Mab 9B9 and streptavidin. Methods: Mab 9B9 was biotinylated with biotin succinimide ester (b-Mab 9B9), while streptavidin (SA) was radiolabeled with 125I. Interaction between b-Mab 9B9 and SA has been estimated in solid-phase radioassay. Radiolabeled SA was conjugated with b- Mab 9B9 or with b-IgG and injected intravenously in rats or perfused in isolated rat lungs. Results: Radiolabeled b-Mab 9B9 biotinylated at biotin- to-antibody molar ratio 10 (b-Mab 9B9) retains its ability to accumulate in rat lungs after intravenous injection. Radiolabeled SA conjugated with b-Mab 9B9 accumulates in the lung tissue in perfused isolated rat lungs. About 20% of injected SA accumulates in the rat lung 1 hr after intravenous injection (localization ratio is 20, immunospecificity of the conjugate pulmonary uptake is 70). As compared with conjugate injection, stepwise intravenous injection of b-Mab 9B9 and radiolabeled SA leads to a marked reduction of SA pulmonary uptake. Maximal pulmonary uptake of Mab 9B9 has been observed 2-3 hr after intravenous injection, while 24 hr later, radioactivity in the lung was markedly reduced. In contrast to radiolabeled Mab 9B9 alone, radiolabeled SA conjugated with b-Mab 9B9 was retained in the lung for at least 48 hr. In concert with effective blood clearance of the conjugate, its prolonged lung retention leads to a marked increase in its lung-to-blood ratio: 80 for SA- b-Mab 9B9 versus 15-20 for Mab 9B9. Conclusion: Conjugation of Mab 9B9 with streptavidin enhances selective pulmonary uptake of the preparation, providing a background for intrapulmonary immunotargeting of various biotinylated agents.

KW - angiotensin-converting enzyme

KW - biotinylated antibody

KW - endothelium

KW - lung

KW - streptavidin

UR - http://www.scopus.com/inward/record.url?scp=0028108307&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0028108307&partnerID=8YFLogxK

M3 - Article

VL - 35

SP - 1358

EP - 1365

JO - Journal of Nuclear Medicine

JF - Journal of Nuclear Medicine

SN - 0161-5505

IS - 8

ER -